跳转至内容
Merck
CN

SML4195

DCZ0415

≥98% (HPLC)

别名:

2-(4-(Pyridin-4-ylmethyl)phenyl)-4,4a,5,5a,6,6a-hexahydro-4,6-ethenocyclopropa[f]isoindole-1,3(2H,3aH)-dione, 4,4a,5,5a,6,6a-Hexahydro-2-[4-(4-pyridinylmethyl)phenyl]-4,6-ethenocycloprop[f]isoindole-1,3(2H,3aH)-dione, DCZ 0415, DCZ-0415

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C23H20N2O2
化学文摘社编号:
分子量:
356.42
NACRES:
NA.21
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


Quality Level

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

Application

DCZ0415 may be used to determine its effects on cell viability, cell cycle distribution, invasive capabilities, and migratory behavior of colorectal cancer (CRC) cells.

Biochem/physiol Actions

DCZ0415 also reduces cyclin D1, β-catenin, and T-cell factor 1 levels, resulting in the inactivation of the Wnt/β-catenin pathway.
DCZ0415 is a TRIP13 inhibitor that exhibits antimyeloma activity in cultures (IC50 in µM = 1.15/U266, 3.25/ARK, 4.13/OCI-MY5, 5.12/ARP-1, 7.4/RPMI-8226, H292/8.02) and in xenograft models in vivo (25 or 50 mg/kg via daily i.p. to mice with MOPC-315 or H929 tumors, respectively) by impairing nonhomologous end-joining (NHEJ) repair and NF-kB activity. Synergistic antimyeloma activity is observed when DCZ0415 is used in combination with the DNA-akylating agent melphalan or the HDAC inhibitor panobinostat.


存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品

此项目有



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Yan Chen et al.
Cell death discovery, 8(1), 35-35 (2022-01-26)
Colorectal cancer (CRC) is one of the digestive tract malignancies whose early symptoms are not obvious. This study aimed to identify novel targets for CRC therapy, especially early-stage CRC, by reanalyzing the publicly available GEO and TCGA databases. Thyroid hormone
Yingcong Wang et al.
Cancer research, 80(3), 536-548 (2019-11-17)
The AAA-ATPase TRIP13 drives multiple myeloma progression. Here, we present the crystal structure of wild-type human TRIP13 at a resolution of 2.6 Å. A small-molecule inhibitor targeting TRIP13 was identified on the basis of the crystal structure. The inhibitor, designated
Sumit Agarwal et al.
Molecular oncology, 16(8), 1728-1745 (2022-02-24)
Thyroid receptor-interacting protein 13 (TRIP13), a protein of the AAA-ATPase family, is upregulated in various human cancers, including colorectal cancer (CRC). This study focused on the inhibition of TRIP13-induced CRC progression and signalling by DCZ0415, a small molecule targeting TRIP13.



全球贸易项目编号

货号GTIN
SML4195-5MG04065272818360
SML4195-25MG04065272818353